Wed, Sep 17, 2014, 6:59 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Cytosorbents Corporation Message Board

  • meifud meifud Sep 10, 2013 12:25 PM Flag

    Zacks is very cautious on hemodefend

    "we had yet to model any financial contribution from HemoDefend given the relatively early stage of development of the product and little visibility as to potential commercialization timelines"
    "today's announcement does not provide substantially more insight into probabilities of eventual commercialization or related timelines"

    in other words, getting the contract award was meaningful in that it keeps hope alive but, as Zacks points out, the Hemodefend idea has been on the radar screen of potential partners for almost two years without attracting any development money...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Fudsy, you are pointing out the obvious. Where did the company mention commercialization timeline or any other hyperbole regarding the announcement? Zacks points that out.
      You are so concerned about acting like a girlyman, that any announcement the company makes ranks another uninformed tirade by you.
      As I mentioned, I appreciated Chan announcing the news, if to only give you some new subject matter. I knew you'd "run it into the ground" ............. we're there.

    • "Relative to potential partners, CTSO most recently noted (on the August business update call) that they are in active discussions with about 20 companies for commercialization of CytoSorb and Hemodefend, combined. For HemoDefend, CTSO is looking at companies involved in blood collection and transfusions. As an example, they had previously mentioned blood bag manufacturers as one type of potential partner (for the "beads in a bag" configuration)."

0.2310.000(0.00%)Sep 17 3:32 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.